Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA

Home / Blog / Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA
Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA
November 07, 2020November 7, 2020
0

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CellProtect, an investigational therapy for multiple myeloma that uses a person’s immune cells to help combat cancer. This designation is given to therapies with the potential to improve medical care for rare disorders, defined as those that affect fewer than 200,000 people in the U.S. It qualifies the therapy’s developer, XNK Therapeutics, for certain incentives, such as tax credits for qualified clinical…

You must be logged in to read/download the full post.

The post Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA appeared first on BioNewsFeeds.